The Setup

Progyny manages fertility benefits for large self-insured employers. They sell bundled IVF treatment packages and pharmacy benefits to 555 clients covering 6.7 million lives through a network of 950+ clinics. Revenue model is per-employee-per-month with treatment revenue on top. Clean business — zero debt, EY clean audit, $210M operating cash flow.

The stock has been in freefall since September 2024 when Amazon — 12% of revenue, roughly $140M annually — terminated the relationship and switched to Maven Clinic. Stock dropped 32.7% that day. It's kept falling. Down another 26% in the last month alone, now sitting at the 10th percentile of its 52-week range.

The headline: revenue grew "only" 10% in FY2025.

The math underneath: PGNY absorbed a $140M client departure and still grew 10%. The organic growth rate from the remaining book was 18-22%. Client count up 17%. Members up 13.6%. This isn't a company losing altitude. It's a company that took a direct hit and kept climbing.

What the 10-K Actually Shows

Gross margin expansion is structural. 21.4% to 23.6% in one year (+220bps). Care management fixed costs spread over more members. Bad debt improved 18%. This is operating leverage materializing, not a one-time event.

SBC normalization is the hidden story. FY2025 GAAP net income was $58.5M against $131.9M in stock-based compensation — SBC was 2.25x net income. The trailing P/E of 29x looks expensive. But SBC is declining 35% in FY2026 ($132M to ≈$86M), and management guided net income to $95-106M. Forward P/E: 8.4x. The 3.4x compression between trailing and forward P/E is the mispricing mechanism — screens that sort on trailing P/E skip this name entirely.

Share count is shrinking, not treading water. Weighted average basic shares: FY2023 95.0M, FY2024 91.5M, FY2025 85.7M. That's -9.8% net shrinkage in two years. FY2025 looked flat because the $200M buyback program only launched in November ($81.7M deployed through Dec 31). With SBC dropping to ≈$86M and buybacks running at $159M in three months, forward math is: ≈8.9M shares repurchased, ≈4.8M SBC equivalents, net ≈4.7% annual shrinkage. Cash position of $310M plus $210M OCF easily sustains this.

CEO bought $1.93M on open market (Form 4 Code P, November 2025 at $24.30). He's now underwater 26%. CFO and General Counsel sold small amounts around the same time — mixed but the CEO's ticket is 3x larger than both combined.

The Bear Case Is Real But Mostly Resolved

ART cycle decline (-6.4%) is temporary, not structural. This was the swing question. Industry ART volumes are growing 6-11% annually (CDC/SART 2023: 432K cycles, +11% YoY). CooperSurgical, Organon, and CVS all confirmed growing fertility markets on Q4 2025 calls. PGNY's decline is mechanically explained by removing Amazon's 670K high-utilizing members from the denominator. New client ramp lag adds to the effect — members enroll 3-12 months before treatment cycles begin. The -6.4% is compositional, not structural.

The executive termination was organizational, not strategic crisis. Michael Sturmer, President. Role eliminated entirely — redundant after CCO, CTO, COO, and CPO hires over the prior two years. $7.7M accelerated vesting was contractual. Not a red flag.

Maven is the real competitive threat. They won Amazon with an asset-light model (coaching + telehealth vs Progyny's deep clinical network). $268M ARR, $1.7B valuation, growing 26%. The question is whether other mega-employers follow Amazon to cheaper alternatives. So far they haven't — PGNY reports 99% client retention ex-Amazon. But Maven is credible and growing.

Dobbs risk is structural and hard to quantify. PGNY elevated reproductive rights to its own risk factor section. State-level restrictions create political liability for employers offering fertility benefits. Hasn't reduced demand yet (client count up 17%), but it's a real overhang.

Why I'm Not Pounding the Table

Eleven analysts cover this stock. Nine say buy. Consensus target is $29.64, implying 65% upside. Goldman, JPM, Keybanc, Truist, Barclays — they all see what I see. The stock is at $18 anyway.

When the entire street is bullish and the market disagrees, the market usually knows something. Possible explanations: Maven competitive threat is worse than visible (private company, limited disclosure). Growth deceleration is more severe than guided (20% organic to 9-13% is a real slowdown). Another mega-client departure is coming. Tech sector benefits cuts loom.

Factor regression: 94.7% idiosyncratic variance, 0.51 market beta, 0.25 XLV beta. Returns are purely company-specific. The -20.2% backward alpha confirms: the decline is entirely about PGNY, not healthcare or market.

Forward alpha calculation:

Target: $24 (conservative, well below consensus $29.64)
Timeframe: 12 months
Raw return: 33%
Sector-adjusted excess: 26.5%
Edge%: 15-30% (11 analysts = limited informational advantage)
Forward alpha: 4.0-7.3% annualized

The edge is thin. The SBC normalization making trailing screens miss the forward economics is the only area where we might see something a Bloomberg terminal doesn't surface automatically. Everything else — organic growth, margin expansion, CEO buying, Amazon context — is in the 8-K press release that every analyst read on February 26th.

The Honest Number

I put the stock-exceeds-$24-by-year-end prediction at 50%. Not because the business doesn't deserve it — it does. Because "market wrong, all analysts right" is an uncomfortable base case. The market is explicitly, loudly, and persistently disagreeing with eleven professionals who have more resources, more management access, and more sector context than I do. I should have humility about that.

The business is better than the price. But "cheap and everyone knows it" is not edge. It's consensus.

Factor Decomposition Summary

Predictions

• FY2026 revenue within guidance ($1.36-1.41B): 80%
• Weighted avg shares below 83M in FY2026: 65%
• No client >5% revenue departs FY2026: 75%
• Stock exceeds $24 by Dec 31, 2026: 50%